SS-31 / Elamipretide
SS-31, now known clinically as elamipretide, is a mitochondria-targeting tetrapeptide that associates with cardiolipin in the inner mitochondrial membrane. After years of clinical development across mitochondrial disorders, the FDA granted accelerated approval in September 2025 to Forzinity (elamipretide) to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg.
Real approval. Narrow indication.
Elamipretide has stronger clinical validation than most compounds discussed in peptide communities. But approval for Barth syndrome does not establish it as a general mitochondrial enhancer, anti-aging therapy or performance drug.
A peptide designed to target the mitochondrial inner membrane.
Elamipretide is a four-amino-acid peptide engineered to accumulate near the inner mitochondrial membrane, where it interacts with cardiolipin—a phospholipid central to mitochondrial structure and energy production.
The scientific premise is that stabilizing mitochondrial membrane function may improve bioenergetics under conditions where mitochondrial performance is impaired. That makes elamipretide different from many “mitochondrial peptides” discussed in biohacking: it has been developed as a pharmaceutical drug and tested in multiple human trials.
More developed than most peptide stories—still not universally positive.
Elamipretide has been studied in randomized clinical trials involving primary mitochondrial myopathy, Barth syndrome and older adults with impaired skeletal-muscle mitochondrial energetics.
In a 2021 randomized trial of older adults, a single dose of elamipretide improved in-vivo skeletal-muscle mitochondrial ATP production—an important mechanistic human result. In primary mitochondrial myopathy, early studies suggested exercise and symptom signals, but the larger phase 3 MMPOWER-3 trial did not establish broad success across its co-primary endpoints.
In Barth syndrome, randomized and open-label data ultimately supported a regulatory pathway. FDA granted accelerated approval in 2025 based on improvement in knee-extensor muscle strength, an intermediate clinical endpoint.
Approval makes the evidence stronger—not broader.
This is where context matters most.
Mitochondrial optimization
Outside rare-disease medicine, discussion tends to focus on energy, recovery, endurance, “mitochondrial repair,” healthy aging and stacking with other mitochondrial compounds.
- Energy and fatigue claims
- Exercise and recovery framing
- Longevity / anti-aging positioning
- Frequent comparison with MOTS-c
Substantial—but indication-specific
Unlike many biohacking peptides, elamipretide has randomized human trials and an FDA-approved drug product. But results differ by disease, endpoint and study design.
- FDA-approved for Barth syndrome
- Randomized mitochondrial-disease trials
- Human ATP-production study
- Broader wellness and longevity claims remain unproven
For the approved Barth syndrome indication, the gap is relatively narrow. For claims about anti-aging, generalized energy enhancement, exercise performance or “mitochondrial optimization” in healthy adults, the gap becomes much wider.
Approved does not mean risk-free—or approved for everything.
Forzinity (elamipretide) received FDA accelerated approval on September 19, 2025 for Barth syndrome patients weighing at least 30 kg.
The approval was based on an improvement in knee-extensor muscle strength, an intermediate clinical endpoint. FDA requires a confirmatory trial to verify clinical benefit, with continued approval potentially contingent on those results.
Clinical studies have commonly reported injection-site reactions. The approved prescribing information also defines product-specific warnings, administration instructions and renal-impairment considerations.
The biggest change is regulatory: SS-31 became a real medicine.
Regulatory
FDA granted accelerated approval to Forzinity.
Elamipretide became the first FDA-approved treatment for Barth syndrome, indicated to improve muscle strength in adult and pediatric patients weighing at least 30 kg.
Research
MMPOWER-3 tested the broader mitochondrial-myopathy thesis.
The phase 3 randomized trial provided a more demanding test of elamipretide in primary mitochondrial myopathy and underscored that promising early signals do not guarantee success across larger clinical endpoints.
Research
Human mitochondrial ATP production improved after a single dose.
A randomized trial in older adults found an improvement in skeletal-muscle mitochondrial ATP production, strengthening the human mechanistic case without proving generalized anti-aging or performance benefits.
Show the receipts.
| Evidence | Design | What it adds | What it cannot prove |
|---|---|---|---|
| PMM dose-escalation · PMID 29500292 | Randomized, placebo-controlled phase I/II | Early exercise-performance signal in genetically confirmed primary mitochondrial myopathy. | Does not establish durable benefit across larger populations. |
| PMM crossover · PMID 32096613 | Randomized crossover trial, n=30 | Suggestive symptom and exercise signals; primary 6MWT endpoint did not reach statistical significance. | Does not establish broad efficacy. |
| Older-adult ATP study · PMID 34264994 | Randomized controlled human physiology study | Demonstrated improved in-vivo skeletal-muscle mitochondrial ATP production after a single dose. | Does not establish longevity, fat loss or athletic-performance benefit. |
| Barth syndrome · PMID 33077895 | Randomized crossover + open-label extension | Generated disease-specific efficacy and safety data that contributed to later development. | Small rare-disease trial; does not support generalized wellness use. |
| MMPOWER-3 · PMID 37268435 | Phase 3 randomized placebo-controlled trial | Provides the most rigorous large-trial test in primary mitochondrial myopathy. | Results in PMM do not define benefit in healthy adults. |
| FDA Forzinity approval · 2025 | Accelerated approval | Establishes elamipretide as an approved drug for Barth syndrome ≥30 kg. | Does not validate off-label biohacking, longevity or generalized mitochondrial-enhancement claims. |
Read deeper.
Follow the evidence.
MOTS-c
Compare an FDA-approved mitochondria-targeting drug with an endogenous mitochondrial peptide whose therapeutic human evidence remains thin.
Tesamorelin
See another example where real approval and strong human evidence apply to a much narrower indication than community use suggests.
What do we actually know?
Explore why clinical-development stage, endpoint quality and approved indication matter more than mechanism alone.
Community Pulse
Track how mitochondrial compounds move from research literature into optimization culture.